for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293

Aug 22 (Reuters) - Eli Lilly And Co :

* Lilly and Astrazeneca receive FDA fast track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

* Also announced planned initiation of a second phase 3 trial for azd3293 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up